SCHEMBL4291944

SCHEMBL4291944

CC(=O)Nc1ccc2c(c1)C(=O)c1cc(NC(C)=O)ccc1C2=O

nearest known ligand 0.92

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.89
MEN1 O00255 2/20 0.89
NPC1 O15118 2/20 0.89
ALDH1A1 P00352 2/20 0.89
MAPT P10636 2/20 0.89
RAB9A P51151 2/20 0.89
KMT2A Q03164 2/20 0.89
SMN1; SMN2 Q16637 2/20 0.89
TERT O14746 3/20 0.61
CYP1A2 P05177 1/20 0.60
POLB P06746 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
ACE2 Q9BYF1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22321720 0.96 MAOA (0.83) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL2812760 0.94 MAOA (1.00) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL9261554 0.93 MAOA (0.97) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL29539012 0.93 MAOA (0.97) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL11475238 0.91 MAOA (0.75) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL21840827 0.89 MAOA (0.90) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL6263718 0.89 MAOA (0.90) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL11481336 0.86 MAPT (0.73) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL6259466 0.86 MAOA (0.69) MAOAMEN1NPC1ALDH1A1MAPT
SCHEMBL3954523 0.85 MAOA (0.84) MAOAMEN1NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 MAOA 1033/4885MEN1 148/4885NPC1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.